Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Democratic Female Senators Praise Supreme Court Nominee Sotomayor
Several Democratic female senators on Wednesday took to the floor in a series of speeches praising Supreme Court nominee Sonia Sotomayor and highlighting her judicial qualifications, the Boston Globe"s "Political Intelligence" reports. Sen. Amy Klobuchar (Minn.) -- a member of the Senate Judiciary Committee -- was joined by Sens. Mary Landrieu (La.), Claire McCaskill (Mo.) and Jeanne Shaheen (N.H.).In her address, Klobuchar said that Sotomayor"s experience "particularly resonated with me," adding that Sotomayor "understands the law is not just some dusty book in your basement" and that its interpretation has consequences. McCaskill said that Sotomayor is a nominee with "integrity, grit, intellect and the ability to pass judgment in the most difficult intellectual challenges that face a Supreme Court justice."According to "Political Intelligence," the floor speeches came after Klobuchar and others praised Sotomayor"s nomination at Monday"s annual convention of the left-leaning legal organization the American Constitution Society. In her speech, Klobuchar defended Sotomayor against conservative critics who have questioned the nominee"s temperament, citing complaints that Sotomayor was impatient with unprepared lawyers. Klobuchar said that she is "hoping that we would get to a point in this country where we could be appointing and confirming as many as rough and to-the-point female judges as we have appointed male judges" ("Political Intelligence," Boston Globe, 6/24).
generic viagra online
Merck Serono Initiates Phase III Study Of Stimuvax In Breast Cancer
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced the initiation of its global Phase III clinical study of the therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine, L-BLP25) in patients with advanced, inoperable breast cancer. The STRIDEa study will determine if Stimuvax can extend progression-free survival in patients treated with hormonal therapy who have hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer. Overall survival, quality of life, tumor response and safety will also be assessed in this study. The STRIDE study will be supervised by an expert Steering Committee and is sponsored by Merck Serono, which is leading the development of Stimuvax.
plastic surgery before after
News of the day
Transplant Drug Stimulates Immune Memory
Rapamycin, a drug given to transplant recipients to suppress their immune systems, has a paradoxical effect on cells responsible for immune memory, scientists at the Emory Vaccine Center have discovered.
Nutrition

Transdel Pharmaceuticals Provides Update On Timing Of Results For Phase 3 Study

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical company focused on developing non-invasive, topically administered products, announced that they anticipate reporting top-line results from their current Phase 3 study of Ketotransdel(R) during the third quarter of 2009. The Phase 3 study consists of a randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of Ketotransdel, a topical cream based non-steroidal anti-inflammatory drug ("NSAID"), in acute soft tissue injuries of the upper and lower extremities. The multi-center trial is being conducted at approximately 30 sites in the United States and will enroll approximately 350 patients. The primary efficacy endpoint is the change from baseline in pain intensity as measured by a Visual Analog Scale (VAS) during daily activities over the past 24 hours at Day 3. If approved by the U.S. Food and Drug Administration ("FDA"), Ketotransdel could become the first topical NSAID cream product in the United States for acute pain management, which is a multi-billion dollar market. The drug could address what the Company believes is a significant unmet medical need for patients and physicians seeking a potentially safer alternative to existing pain management approaches, such as oral NSAIDs. If and when the FDA approves Ketotransdel for treatment of acute pain, we intend to pursue FDA approval of Ketotransdel for other indications, such as osteoarthritis. Furthermore, we are either in or pursuing discussions with U.S. and foreign based potential partners with sales and marketing infrastructures to support Ketotransdel in the event that the product is approved and commercialized. We believe that the clinical success of Ketotransdel will facilitate the use of the Transdel(TM) delivery technology in other products. We have identified co-development opportunities for potential products in pain management and other therapeutic areas utilizing the Transdel(TM) platform technology and we are exploring potential partnerships for these identified products. Some of these identified co-development areas include hormone based products, antiemetic and dermatological products. We are also looking to out-license our Transdel(TM) drug delivery technology for the development and commercialization of additional innovative drug products. About Transdel Pharmaceuticals, Inc. Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company"s innovative-patented Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. The Company is actively investigating other product candidates for transdermal delivery using the Transdel(TM) platform technology and is also actively pursuing partnerships with other groups or companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products. The Company recently announced that they entered into a license agreement with JH Direct, LLC for the exclusive worldwide rights to Transdel"s anti-cellulite cosmeceutical product which utilizes the Company"s Transdel(TM) technology. Safe Harbor Statement Statements made in this release that are not historical in nature constitute forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Please note that forward-looking statements are based on projections, that these projections involve judgment, and that individual judgments may vary. Moreover, these statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of the Company"s future financial results and its ability to raise additional funds to support its operations, its ability to complete the required clinical trials and obtain FDA approval for Ketotransdel, the efficacy and the commercial success of any cosmetic/cosmeceutical products it develops, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company"s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Transdel Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009